Global incidence of prostate cancer in developing and developed countries with changing age structures

Autoři: Jeremy Y. C. Teoh aff001;  Hoyee W. Hirai aff002;  Jason M. W. Ho aff002;  Felix C. H. Chan aff002;  Kelvin K. F. Tsoi aff002;  Chi Fai Ng aff001
Působiště autorů: S.H. Ho Urology Centre, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong aff001;  Stanley Ho Big Data Decision Analytics Research Centre, The Chinese University of Hong Kong, Hong Kong, Hong Kong aff002;  Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, Hong Kong aff003
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
doi: 10.1371/journal.pone.0221775


To investigate the global incidence of prostate cancer with special attention to the changing age structures. Data regarding the cancer incidence and population statistics were retrieved from the International Agency for Research on Cancer in World Health Organization. Eight developing and developed jurisdictions in Asia and the Western countries were selected for global comparison. Time series were constructed based on the cancer incidence rates from 1988 to 2007. The incidence rate of the population aged ≥ 65 was adjusted by the increasing proportion of elderly population, and was defined as the “aging-adjusted incidence rate”. Cancer incidence and population were then projected to 2030. The aging-adjusted incidence rates of prostate cancer in Asia (Hong Kong, Japan and China) and the developing Western countries (Costa Rica and Croatia) had increased progressively with time. In the developed Western countries (the United States, the United Kingdom and Sweden), we observed initial increases in the aging-adjusted incidence rates of prostate cancer, which then gradually plateaued and even decreased with time. Projections showed that the aging-adjusted incidence rates of prostate cancer in Asia and the developing Western countries were expected to increase in much larger extents than the developed Western countries.

Klíčová slova:

Asia – Elderly – Hong Kong – Prostate cancer – Sweden – United Kingdom – Costa Rica – Croatia


1. Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead. Lancet. 2009;374(9696):1196–208. doi: 10.1016/S0140-6736(09)61460-4 19801098; PubMed Central PMCID: PMC2810516.

2. World Health Organization. Global Health Observatory data repository., accessed [1st July 2017].

3. U.S. Cancer Statistics Working Group. US cancer statistics: 1999–2009 incidence and mortality web-based report. Atlanta GA: USDHHS, CDC; 2013.

4. Bell KJ, Del Mar C, Wright G, Dickinson J, Glasziou P. Prevalence of incidental prostate cancer: A systematic review of autopsy studies. Int J Cancer. 2015;137(7):1749–57. doi: 10.1002/ijc.29538 25821151; PubMed Central PMCID: PMC4682465.

5. Wong MC, Goggins WB, Wang HH, Fung FD, Leung C, Wong SY, et al. Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries. Eur Urol. 2016;70(5):862–74. doi: 10.1016/j.eururo.2016.05.043 27289567.

6. Krahn MD, Bremner KE, Zagorski B, Alibhai SM, Chen W, Tomlinson G, et al. Health care costs for state transition models in prostate cancer. Med Decis Making. 2014;34(3):366–78. doi: 10.1177/0272989X13493970 23894082.

7. Krahn MD, Bremner KE, Luo J, Alibhai SM. Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events. Curr Oncol. 2014;21(3):e457–65. doi: 10.3747/co.21.1865 24940106; PubMed Central PMCID: PMC4059810.

8. Neutel CI, Gao RN, Blood PA, Gaudette LA. The changing age distribution of prostate cancer in Canada. Can J Public Health. 2007;98(1):60–4. 17278680.

9. Bray F, Moller B. Predicting the future burden of cancer. Nat Rev Cancer. 2006;6(1):63–74. doi: 10.1038/nrc1781 16372017.

10. Tsoi KKF, Hirai HW, Chan FCH, Griffiths S, Sung JJY. Predicted Increases in Incidence of Colorectal Cancer in Developed and Developing Regions, in Association With Ageing Populations. Clin Gastroenterol Hepatol. 2017;15(6):892–900 e4. doi: 10.1016/j.cgh.2016.09.155 27720911.

11. Ferlay J, Bray F, Steliarova-Foucher E, Forman D. Cancer Incidence in Five Continents, CI5plus. IARC CancerBase No. 9. Lyon: International Agency for Research on Cancer; 2014. Available from:, accessed [1st July 2017].

12. The World Bank. The World Bank Atlas method—detailed methodology. Available from:, accessed [1st July 2017].

13. Tsoi KK, Hirai HW, Chan FC, Griffiths S, Sung JJ. Cancer burden with ageing population in urban regions in China: projection on cancer registry data from World Health Organization. Br Med Bull. 2017;121(1):83–94. doi: 10.1093/bmb/ldw050 27913398.

14. Kwiatkowski D, Phillips PCB, Schmidt P, Shin Y. Testing the null hypothesis of stationarity against the alternative of a unit root: How sure are we that economic time series have a unit root? Journal of Econometrics. 1992;54(1):159–78.

15. Fan J, Gijbels I. Local polynomial modelling and its applicaitons. London: Chapman and Hall, 1996.

16. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86. doi: 10.1002/ijc.29210 25220842.

17. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R, Inoue M. Age standardization of rates: a new WHO standard. World Health Organization 2001. GPE Discussion Paper Series: No. 31. Available at: Accessed 1st July 2017.

18. Brawley OW. Prostate cancer epidemiology in the United States. World J Urol. 2012;30(2):195–200. doi: 10.1007/s00345-012-0824-2 22476558.

19. Hoffman RM, Meisner AL, Arap W, Barry M, Shah SK, Zeliadt SB, et al. Trends in United States Prostate Cancer Incidence Rates by Age and Stage, 1995–2012. Cancer Epidemiol Biomarkers Prev. 2016;25(2):259–63. doi: 10.1158/1055-9965.EPI-15-0723 26646364.

20. Aslani A, Minnillo BJ, Johnson B, Cherullo EE, Ponsky LE, Abouassaly R. The impact of recent screening recommendations on prostate cancer screening in a large health care system. J Urol. 2014;191(6):1737–42. doi: 10.1016/j.juro.2013.12.010 24342148.

21. Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC, Brawley O, et al. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. JAMA. 2015;314(19):2054–61. doi: 10.1001/jama.2015.14905 26575061.

Článek vyšel v časopise


2019 Číslo 10